Analysts Set Thermo Fisher Scientific Inc. (NYSE:TMO) Price Target at $589.38

Thermo Fisher Scientific Inc. (NYSE:TMO) has received an average recommendation of “Moderate Buy” from the twenty-two brokerages that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and seventeen have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $592.2381.

Several research firms have commented on TMO. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating on the stock. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, UBS Group increased their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TMO. Bernard Wealth Management Corp. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC grew its position in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific during the first quarter valued at approximately $30,000. Finally, Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific during the first quarter valued at approximately $31,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $479.48 on Tuesday. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75. The company has a fifty day moving average price of $466.86 and a 200-day moving average price of $451.08.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.